NASDAQ:CMPS

COMPASS Pathways Competitors

$34.35

+0.32 (+0.94 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$33.92

Now: $34.35▼

$35.18

50-Day Range

$34.75

MA: $39.71▼

$50.11

52-Week Range

$22.51

Now: $34.35▼

$61.69

Volume308,409 shs

Average Volume394,836 shs

Market Capitalization$1.26 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

COMPASS Pathways (NASDAQ:CMPS) Vs. BHVN, SAGE, HCM, EBS, IMAB, and ARNA

Should you be buying CMPS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to COMPASS Pathways, including Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), I-Mab (IMAB), and Arena Pharmaceuticals (ARNA).

COMPASS Pathways vs. Biohaven Pharmaceutical Stock

COMPASS Pathways (NASDAQ:CMPS) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Profitability

This table compares COMPASS Pathways and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	N/A	N/A
Biohaven Pharmaceutical	N/A	-1,091.41%	-120.85%

Analyst Ratings

This is a summary of current ratings and price targets for COMPASS Pathways and Biohaven Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	0	0	6	0	3.00
Biohaven Pharmaceutical	0	2	10	0	2.83

COMPASS Pathways presently has a consensus target price of $70.75, suggesting a potential upside of 105.97%. Biohaven Pharmaceutical has a consensus target price of $96.4545, suggesting a potential upside of 29.37%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe COMPASS Pathways is more favorable than Biohaven Pharmaceutical.

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares COMPASS Pathways and Biohaven Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A
Biohaven Pharmaceutical	N/A	N/A	$-528,800,000.00	($10.91)	-6.83

Summary

COMPASS Pathways beats Biohaven Pharmaceutical on 5 of the 8 factors compared between the two stocks.

COMPASS Pathways vs. Sage Therapeutics Stock

Sage Therapeutics (NASDAQ:SAGE) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Sage Therapeutics and COMPASS Pathways' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sage Therapeutics	$6.87 million	646.96	$-680,240,000.00	($13.38)	-5.69
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A

COMPASS Pathways has lower revenue, but higher earnings than Sage Therapeutics.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sage Therapeutics and COMPASS Pathways, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sage Therapeutics	0	8	8	0	2.50
COMPASS Pathways	0	0	6	0	3.00

Sage Therapeutics presently has a consensus price target of $87.0625, indicating a potential upside of 14.36%. COMPASS Pathways has a consensus price target of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Sage Therapeutics.

Institutional & Insider Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Sage Therapeutics and COMPASS Pathways' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sage Therapeutics	-7,706.84%	-63.81%	-56.64%
COMPASS Pathways	N/A	N/A	N/A

Summary

COMPASS Pathways beats Sage Therapeutics on 7 of the 10 factors compared between the two stocks.

COMPASS Pathways vs. Hutchison China MediTech Stock

Hutchison China MediTech (NASDAQ:HCM) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Hutchison China MediTech and COMPASS Pathways' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hutchison China MediTech	N/A	N/A	N/A
COMPASS Pathways	N/A	N/A	N/A

Earnings and Valuation

This table compares Hutchison China MediTech and COMPASS Pathways' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hutchison China MediTech	$204.89 million	20.65	$-106,020,000.00	($0.80)	-36.33
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A

COMPASS Pathways has lower revenue, but higher earnings than Hutchison China MediTech.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Hutchison China MediTech and COMPASS Pathways, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hutchison China MediTech	0	0	2	0	3.00
COMPASS Pathways	0	0	6	0	3.00

Hutchison China MediTech presently has a consensus target price of $40.00, indicating a potential upside of 37.65%. COMPASS Pathways has a consensus target price of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than Hutchison China MediTech.

Summary

COMPASS Pathways beats Hutchison China MediTech on 3 of the 5 factors compared between the two stocks.

COMPASS Pathways vs. Emergent BioSolutions Stock

COMPASS Pathways (NASDAQ:CMPS) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares COMPASS Pathways and Emergent BioSolutions' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
COMPASS Pathways	N/A	N/A	N/A
Emergent BioSolutions	12.50%	26.68%	12.70%

Valuation & Earnings

This table compares COMPASS Pathways and Emergent BioSolutions' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A
Emergent BioSolutions	$1.11 billion	3.76	$54.50 million	$2.91	26.68

Emergent BioSolutions has higher revenue and earnings than COMPASS Pathways.

Insider and Institutional Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for COMPASS Pathways and Emergent BioSolutions, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
COMPASS Pathways	0	0	6	0	3.00
Emergent BioSolutions	0	2	5	0	2.71

COMPASS Pathways presently has a consensus price target of $70.75, suggesting a potential upside of 105.97%. Emergent BioSolutions has a consensus price target of $113.6667, suggesting a potential upside of 46.40%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Emergent BioSolutions.

Summary

Emergent BioSolutions beats COMPASS Pathways on 7 of the 10 factors compared between the two stocks.

COMPASS Pathways vs. I-Mab Stock

I-Mab (NASDAQ:IMAB) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for I-Mab and COMPASS Pathways, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0	0	4	0	3.00
COMPASS Pathways	0	0	6	0	3.00

I-Mab presently has a consensus target price of $70.00, suggesting a potential upside of 22.81%. COMPASS Pathways has a consensus target price of $70.75, suggesting a potential upside of 105.97%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than I-Mab.

Valuation and Earnings

This table compares I-Mab and COMPASS Pathways' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$4.31 million	951.50	$-208,560,000.00	($28.90)	-1.97
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A

COMPASS Pathways has lower revenue, but higher earnings than I-Mab.

Institutional & Insider Ownership

16.6% of I-Mab shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares I-Mab and COMPASS Pathways' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
COMPASS Pathways	N/A	N/A	N/A

Summary

COMPASS Pathways beats I-Mab on 3 of the 5 factors compared between the two stocks.

COMPASS Pathways vs. Arena Pharmaceuticals Stock

Arena Pharmaceuticals (NASDAQ:ARNA) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Arena Pharmaceuticals and COMPASS Pathways, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arena Pharmaceuticals	0	0	15	0	3.00
COMPASS Pathways	0	0	6	0	3.00

Arena Pharmaceuticals presently has a consensus target price of $92.80, indicating a potential upside of 38.34%. COMPASS Pathways has a consensus target price of $70.75, indicating a potential upside of 105.97%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than Arena Pharmaceuticals.

Earnings and Valuation

This table compares Arena Pharmaceuticals and COMPASS Pathways' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arena Pharmaceuticals	$806.43 million	5.02	$397.55 million	$7.69	8.72
COMPASS Pathways	N/A	N/A	$-19,610,000.00	N/A	N/A

Arena Pharmaceuticals has higher revenue and earnings than COMPASS Pathways.

Profitability

This table compares Arena Pharmaceuticals and COMPASS Pathways' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arena Pharmaceuticals	N/A	-33.17%	-30.41%
COMPASS Pathways	N/A	N/A	N/A

Institutional and Insider Ownership

89.7% of Arena Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Arena Pharmaceuticals beats COMPASS Pathways on 5 of the 8 factors compared between the two stocks.